Rachel Rubin

Rachel Rimsky Rubin is a healthcare and biotech executive with extensive experience in business operations, investments, and program management. She previously served as Vice President of Investments and Programs at Roivant Social Ventures, a not-for-profit social impact organization focused on improving healthcare access and outcomes for underserved groups.13

Prior to her role at Roivant Social Ventures, Rubin held the position of Principal at Roivant Health, a subsidiary of Roivant Sciences. There, she led business operations to launch start-ups across healthcare technology and biotechs, including companies like Datavant.3

Rubin's career trajectory includes:

• Chief Operating Officer at Oviva Therapeutics (September 2023 - July 2024)
• Advisor at Invisible Technologies Inc. (June 2023 - Present)
• Board Advisor at NovaXS Biotech Corp. (January 2023 - December 2023)

Her experience at Roivant Sciences spanned from August 2017 to November 2022, where she played key roles in both Roivant Health and Roivant Social Ventures.3

Rubin's background in investment management is evident from her earlier career, where she worked as Vice President of the Alternative Investments and Manager Selection business at Goldman Sachs and held hedge fund investment roles at financial institutions GAM and Deutsche Bank.2

Currently, as of January 2025, Rachel Rimsky Rubin is serving as the Head of Operations at Adelphi Data, a position she has held since August 2024.3